Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

May 23, 2013
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer

May 13, 2013
Merrimack Reports First Quarter 2013 Financial Results

View all »Events & Presentations

Jun 4, 2013 at 9:30 AM ET
Merrimack Pharmaceuticals To Present at Jefferies 2013 Global Healthcare Conference

Stock Quote (NASDAQ: MACK)

Price:
5.26

Change:
+ 0.15

Day High:
5.32

Day Low:
5.01

Volume:
378,200

4:00 PM ET on May 23, 2013
Delayed ~20 min. By eSignal.

Shareholder Tools